Prevalence of depressive syndrome in patients with breast cancer treated with or without aromatase inhibitors

Aims Women with breast cancer are at higher risk of suffering from a depressive syndrome.We aim to observe the prevalence of depressive syndrome in patients with breast cancer treated with aromatase inhibitors (AI) and in a control group without hormonal therapy.